AU StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

IMMUTEP LTD

0.030

-0.001-3.23%

Volume:12.58M

Turnover:374.70K

Market Cap:44.21M

PE:-0.56

High:0.032

Open:0.031

Low:0.029

Close:0.031

52wk High:0.470

52wk Low:0.028

Shares:1.47B

Float Shares:1.23B

Volume Ratio:1.28

T/O Rate:1.02%

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.054

EPS(LYR):-0.054

ROE:-77.31%

ROA:-42.45%

PB:0.72

PE(LYR):-0.56

Loading ...

Overview Company News Filings

Immutep Says Pete Meyers Resigns as Deputy Chairman and Non-Executive Director

Immutep - Pete Meyers Resigns as Non-Executive Director and Deputy Chairman Effective Oct 2, 2026

THOMSON REUTERS

Immutep Ltd-Resignation of Non-Executive Director

THOMSON REUTERS

Immutep Receives A$ 856,669 Australian R&D Tax Incentive Cash Rebate

NASDAQ Trade Halt Halt News Pending at 07:50 Pm

Immutep Plans Reverse Split of Nasdaq-Listed American Depositary Shares

MT Newswires Live

Immutep - Ads Ratio Changes to 1 Ads = 200 Ordinary Shares Effective Sept 28, 2026

THOMSON REUTERS

Immutep - Announces Change to Ads Ratio Quoted on NASDAQ

THOMSON REUTERS

Immutep Ltd-Change to American Depositary Share Ratio

THOMSON REUTERS

Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says

MT Newswires Live

Immutep Gets a New Bull at Jefferies

Immutep - to Focus Efti Development on Hnscc with CPS < 1 and Neoadjuvant Sts

THOMSON REUTERS

Immutep - Contracts New Manufacturing Run of Efti at 200 L Scale

THOMSON REUTERS

Immutep - Targets Next Efti Clinical Trials Start in 2H Cy2027

THOMSON REUTERS

Immutep Targets 2H 2027 Start for Efti Trials in PD-L1-Negative Head and Neck Cancer, Soft Tissue Sarcoma

Immutep Says Root Cause Analysis Points to Structural Differences in Drug Candidate Used in Discontinued Trial

MT Newswires Live

Immutep Ltd-Immutep Outlines Focused Development Strategy for Efti

THOMSON REUTERS

Australia's Immutep Falls to Near 3-Week Low as 2026 Loss Widens

Immutep Says no Dividends Paid or Declared During Current FY

Immutep - FY Loss Attributable A$79.3 Mln

THOMSON REUTERS

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.tigrgood.cn/stock/IMM.AU/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMM.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","market":"AU","secType":"STK","nameCN":"IMMUTEP LTD","latestPrice":0.03,"timestamp":1791349920000,"preClose":0.031,"halted":0,"volume":12583749,"delay":0,"changeRate":-0.03225806451612906,"nameEN":"IMMUTEP LTD","floatShares":1228247159,"shares":1473721306,"eps":-0.0539,"marketStatus":"Not Yet Opened","change":-0.001,"latestTime":"10-07 16:12:00 AEDT","open":0.031,"high":0.032,"low":0.029,"amount":374704,"amplitude":0.096774,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.0539,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":0,"beginTime":1791414000000},"marketStatusCode":0,"adr":0,"exchange":"ASX","adjPreClose":0.031,"openAndCloseTimeList":[[1791327600000,1791349200000]],"volumeRatio":1.2819219865848537,"lotSize":1,"tradeCurrency":"AUD","auctionPricing":{"symbol":"IMM.AU","preClose":0.031,"auctionPrice":0.03,"auctionVolume":1109844,"auction":3,"marketStatus":"盘后竞价","timestamp":1791349804121}},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:true,,method:\"POST\",data:#items:@#symbol:\"IMM.AU\",,,,,undefined,":{"symbol":"IMM.AU","floatShares":1228247159,"roa":"-42.45%","roe":"-77.31%","lyrEps":-0.0539,"volumeRatio":1.2819219865848537,"shares":1473721306,"dividePrice":0,"high":0.032,"amplitude":0.096774,"preClose":0.031,"low":0.029,"week52Low":0.028,"pbRate":"0.72","psRate":"2.22","week52High":0.47,"institutionHeld":0,"latestPrice":0.03,"eps":-0.0539,"divideRate":0,"volume":12583749,"delay":0,"ttmEps":-0.0539,"open":0.031,"prevYearClose":0.415,"prevWeekClose":0.032,"prevMonthClose":0.034,"prevQuarterClose":0.034,"fiveDayClose":0.034,"twentyDayClose":0.046,"sixtyDayClose":0.057,"dividendGrowthYears":0,"fiveYearAvgDividendRate":0},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMM.AU\",params:#limit:5,,,undefined,":[{"market":"AU","date":"2024-06-05","symbol":"IMM.AU","defaultRemindTime":1717545600000,"type":"split","dateTimestamp":1717509600000,"forFactor":948148,"toFactor":1000000,"ratio":0.9481480000000001}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMM.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMM.AU\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2673377697","title":"Immutep Says Pete Meyers Resigns as Deputy Chairman and Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2673377697","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673377697?lang=en_us&edition=fundamental","pubTime":"2026-10-05 06:42","pubTimestamp":1791153759,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Says Pete Meyers Resigns as Deputy Chairman and Non-Executive DirectorOct 5 (Reuters)-Immutep LtdIMM.AX:RESIGNATION OF NON-EXECUTIVE DIRECTORPETE MEYERS RESIGNS AS NON-EXECUTIVE DIRECTOR AND DEPUTY CHAIRMAN EFFECTIVE OCT 2, 2026Further company coverage:IMM.AX","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE75JFZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673776981","title":"Immutep - Pete Meyers Resigns as Non-Executive Director and Deputy Chairman Effective Oct 2, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2673776981","media":"THOMSON REUTERS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673776981?lang=en_us&edition=fundamental","pubTime":"2026-10-05 06:37","pubTimestamp":1791153477,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE75JFZJ:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2673677698","title":"Immutep Ltd-Resignation of Non-Executive Director","url":"https://stock-news.laohu8.com/highlight/detail?id=2673677698","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2673677698?lang=en_us&edition=fundamental","pubTime":"2026-10-05 06:37","pubTimestamp":1791153477,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261004:nTUE75JFZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2671226246","title":"Immutep Receives A$ 856,669 Australian R&D Tax Incentive Cash Rebate","url":"https://stock-news.laohu8.com/highlight/detail?id=2671226246","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2671226246?lang=en_us&edition=fundamental","pubTime":"2026-09-30 09:15","pubTimestamp":1790730903,"startTime":"0","endTime":"0","summary":"Immutep receives A$ 856,669 Australian R&D tax incentive cash rebateImmutep received an A$ 856,669 cash rebate under Australia’s R&D tax incentive program for eligible 2025 fiscal-year spending.AusInd","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260930:nNDL3wCmPK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670208384","title":"NASDAQ Trade Halt Halt News Pending at 07:50 Pm","url":"https://stock-news.laohu8.com/highlight/detail?id=2670208384","media":"Reuters","labels":["event"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2670208384?lang=en_us&edition=fundamental","pubTime":"2026-09-26 07:50","pubTimestamp":1790380200,"startTime":"0","endTime":"0","summary":"NASDAQ TRADE HALTHALT NEWS PENDING AT 07:50 PM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260925:nAQN2MKW2S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"event","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMMP","BK7508","BK7067","IMM.AU","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669195643","title":"Immutep Plans Reverse Split of Nasdaq-Listed American Depositary Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2669195643","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669195643?lang=en_us&edition=fundamental","pubTime":"2026-09-22 05:52","pubTimestamp":1790027561,"startTime":"0","endTime":"0","summary":"Immutep  said it will change the ratio of its Nasdaq-listed American depositary shares  to 1 ADS representing 200 ordinary shares from 1 ADS representing 10 ordinary shares, equivalent to a 1-for-20 ADS reverse split, effective Sept. 28, according to a late Monday statement by the company.The move is intended to help the company regain compliance with Nasdaq's $1 minimum bid-price requirement, following 30 consecutive business days of trading below that threshold.The change will not affect the company's Australian Securities Exchange-listed shares, share capital, cash position or clinical programs, while fractional ADSs will be sold and the proceeds distributed to eligible holders.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4117","AFG","BK7067","LCLG","BK4107","NQmain","BK7508","BK7016","IMM.AU","ADS.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669316355","title":"Immutep - Ads Ratio Changes to 1 Ads = 200 Ordinary Shares Effective Sept 28, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2669316355","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669316355?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:01","pubTimestamp":1789992111,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0RL:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669163323","title":"Immutep - Announces Change to Ads Ratio Quoted on NASDAQ","url":"https://stock-news.laohu8.com/highlight/detail?id=2669163323","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669163323?lang=en_us&edition=fundamental","pubTime":"2026-09-21 20:01","pubTimestamp":1789992111,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nFWN45A0RL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2669139744","title":"Immutep Ltd-Change to American Depositary Share Ratio","url":"https://stock-news.laohu8.com/highlight/detail?id=2669139744","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2669139744?lang=en_us&edition=fundamental","pubTime":"2026-09-21 10:39","pubTimestamp":1789958383,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260921:nTUE29TKJ0:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667616451","title":"Immutep's Drug Candidate Now Has Clearer Potential Development Path, Jefferies Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2667616451","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667616451?lang=en_us&edition=fundamental","pubTime":"2026-09-15 13:33","pubTimestamp":1789450429,"startTime":"0","endTime":"0","summary":"Immutep's  eftilagimod alfa drug candidate, or efti, now has a clearer potential development path after the early termination of the TACTI-004 study, according to a Tuesday note by Jefferies.Its root cause analysis increasingly supports TACTI-004 as a potentially isolated product-specific structural issue rather than a failure of efti's biology. The identification of subtle N-glycan differences in the efti material used in TACTI-004 is potentially important.With prior efti data intact, head and neck squamous cell carcinoma prioritization, fast-track status, and planned manufacturing work, the risk and reward look more constructive despite residual execution risk.The brokerage upgraded its rating on Immutep to buy from hold with the price target rising to AU$0.08 per share from AU$0.04.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667692474","title":"Immutep Gets a New Bull at Jefferies","url":"https://stock-news.laohu8.com/highlight/detail?id=2667692474","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2667692474?lang=en_us&edition=fundamental","pubTime":"2026-09-15 09:09","pubTimestamp":1789434540,"startTime":"0","endTime":"0","summary":"0109 GMT - Immutep gets a new bull at Jefferies, where analyst David Stanton sees a clearer potential development path for the biotechnology company's lead product candidate. Raising his recommendation to buy from hold, Stanton is encouraged by the Australian company's update that the early discontinuation of a lung cancer study doesn't appear to be linked to clinical factors or trial execution. Emerging evidence supports a cautiously constructive view that the outcome stemmed from an isolated manufacturing or product-characterisation issue, Stanton explains in a note to clients. Risk/reward looks more constructive to Stanton, who now includes Immutep's phase IIhead and neck squamous cell carcinoma opportunity in his valuation. Jefferies doubles its target price to 8 Australian cents. Shares are flat at 4.7 Australian cents.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMM.AU","IMMP","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666521234","title":"Immutep - to Focus Efti Development on Hnscc with CPS < 1 and Neoadjuvant Sts","url":"https://stock-news.laohu8.com/highlight/detail?id=2666521234","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666521234?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128036,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F5:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7508","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666212615","title":"Immutep - Contracts New Manufacturing Run of Efti at 200 L Scale","url":"https://stock-news.laohu8.com/highlight/detail?id=2666212615","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666212615?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128036,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F5:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666212325","title":"Immutep - Targets Next Efti Clinical Trials Start in 2H Cy2027","url":"https://stock-news.laohu8.com/highlight/detail?id=2666212325","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666212325?lang=en_us&edition=fundamental","pubTime":"2026-09-11 20:00","pubTimestamp":1789128036,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nFWN4530F5:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666151081","title":"Immutep Targets 2H 2027 Start for Efti Trials in PD-L1-Negative Head and Neck Cancer, Soft Tissue Sarcoma","url":"https://stock-news.laohu8.com/highlight/detail?id=2666151081","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666151081?lang=en_us&edition=fundamental","pubTime":"2026-09-11 10:32","pubTimestamp":1789093949,"startTime":"0","endTime":"0","summary":"Immutep targets 2H 2027 start for efti trials in PD-L1-negative head and neck cancer, soft tissue sarcomaImmutep reset efti’s registration strategy, prioritizing head and neck cancer in PDL1negative p","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260911:nNDL8SLnt4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666512317","title":"Immutep Says Root Cause Analysis Points to Structural Differences in Drug Candidate Used in Discontinued Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2666512317","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666512317?lang=en_us&edition=fundamental","pubTime":"2026-09-11 09:02","pubTimestamp":1789088547,"startTime":"0","endTime":"0","summary":"Immutep  conducted a root cause analysis covering clinical, pharmacological, and manufacturing aspects for its eftilagimod alfa drug candidate, or efti, which identified structural differences between the efti used in the discontinued TACTI-004 trial and the efti used in earlier successful clinical studies, according to a Friday Australian bourse filing.The differences, including a difference in N-glycan structure, are considered potentially relevant given the different immune activation profile observed in the TACTI-004 trial. Immutep believes that \"the unexpected outcome of TACTI-004\" cannot be explained by clinical factors or trial execution factors.Due to the analytical differences between efti manufactured at 200 L scale and efti manufactured at 2,000 L scale, a new manufacturing run of efti at 200 L scale was contracted.Future registration-directed clinical development of efti is intended to focus on head and neck squamous cell carcinoma in patients with negative PD-L1 expression","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7508","BK4505","ROOT","BK7067","BK4551","IMM.AU","BK4107"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666519409","title":"Immutep Ltd-Immutep Outlines Focused Development Strategy for Efti","url":"https://stock-news.laohu8.com/highlight/detail?id=2666519409","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666519409?lang=en_us&edition=fundamental","pubTime":"2026-09-11 07:01","pubTimestamp":1789081308,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260910:nTUE9KKQV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMM.AU","BK7067"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663021517","title":"Australia's Immutep Falls to Near 3-Week Low as 2026 Loss Widens","url":"https://stock-news.laohu8.com/highlight/detail?id=2663021517","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663021517?lang=en_us&edition=fundamental","pubTime":"2026-08-31 11:40","pubTimestamp":1788147609,"startTime":"0","endTime":"0","summary":"BUZZ-Australia's Immutep falls to near 3-week low as 2026 loss widens** Shares of ImmutepIMM.AXfell as much as 4% to A$0.048, marking their lowest level since August 12** Biotechnology firm'sannual losswidens by 29.1% to A$79.3 million  from A$61.4 million in 2025** Including day's moves, stock down 88.2% YTD","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nL4N44S09S:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMM.AU","BK7067","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663025976","title":"Immutep Says no Dividends Paid or Declared During Current FY","url":"https://stock-news.laohu8.com/highlight/detail?id=2663025976","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663025976?lang=en_us&edition=fundamental","pubTime":"2026-08-31 09:32","pubTimestamp":1788139963,"startTime":"0","endTime":"0","summary":"BRIEF-Immutep Says No Dividends Paid Or Declared During Current FYAug 31 (Reuters)-Immutep LtdIMM.AX:IMMUTEP LTD -  NO DIVIDENDS PAID OR DECLARED DURING CURRENT FYFurther company coverage:IMM.AX","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260831:nFWN44P20Y:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK7067","IMM.AU","BK7508"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663040149","title":"Immutep - FY Loss Attributable A$79.3 Mln","url":"https://stock-news.laohu8.com/highlight/detail?id=2663040149","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663040149?lang=en_us&edition=fundamental","pubTime":"2026-08-31 07:14","pubTimestamp":1788131660,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260830:nPLXZ3JZPT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","BK7067","IMM.AU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":4,"pageCount":1,"totalSize":61,"code":"91000000","status":"200"}]}}